Product profile
Calvin-40
Calvin-40 is Wandercraft self-balancing exoskeleton for rehabilitation and personal mobility, supporting gait therapy in clinical settings.
Facts
- Company
- Wandercraft
- Product type
- humanoid
- Status
- deployed
- Primary capability
- manipulation
- Website
- https://en.wandercraft.eu/calvin-40
About Calvin-40
Calvin-40 is Wandercraft's humanoid robot for industrial and logistics work. It is designed for heavy handling and precision tasks, using high-torque actuation, vision, autonomous navigation and whole-body control that adapts to the carried load.
Wandercraft is industrialising Calvin with Renault Group and reports initial assembly-line deployment in Europe. The company presents a certifiable safety architecture and targets strenuous workflows, while operating hours, reliability and use-case coverage remain development targets or company-attributed results.
Market context
humanoid, humanoid
Summary
Type: Exoskeleton
Core: Gait rehab
Function: Walking aid
Audience: Healthcare
Specifications
- deployment_maturity
- Launch in collaboration with Groupe Renault
- force_torque_sensing
- Feet with force sensors
- modularity
- Modular design customizable for various use cases
- operational_environment
- Factory floor
- payload_capacity_kg
- 40 kg
- status_display
- LED light strips communicate status to nearby operators
- vision_system
- Day/night camera manipulation, navigation, and obstacle avoidance
Operations
- Environment
- industrial production, assembly lines, logistics
- Primary user
- industrial operators, logistics teams
- Role
- heavy-load handling, precision manipulation, strenuous task support
- Interaction model
- autonomous task execution, work alongside industrial staff
- Mobility class
- biped humanoid
- Product detail
- humanoid, humanoid
Research, Articles and recent verified events
- Ecuador authorises Wandercraft Atalante X for clinical rehabilitation — 2026-07-27
- Renault Group deploys 350 Wandercraft Calvin-40 humanoid robots — 2026-03-12
- Atalante X powered exoskeleton highlighted in rehabilitation study — 2025-08-01
- Wandercraft secures €64.3 million in Series D funding — 2025-06-11
- Wandercraft's Atalante X receives second FDA clearance — 2024-02-13
- Wandercraft secures €25M EIB financing for exoskeleton development — 2023-12-28